---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-25-000097"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:00:12.719354+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics Q1 net loss $56.2M, cuts workforce 45% to extend cash runway

## Summary
- Net loss of $56.2M in Q1 2025 vs $47.0M prior-year; R&D expenses rose to $43.4M on BEACON-IPF close-out.
- Announced ~45% workforce reduction on May 1, 2025, expected to be substantially completed by Q2 2025.
- Cash, cash equivalents and short-term investments totaled $307.1M as of March 31, 2025.
- BEACON-IPF topline data expected in Q2 2025; close-out activities ongoing.
- Interim Phase 1 data for PLN-101095 plus pembrolizumab showed three confirmed partial responses in six patients at highest dose.

## SEC filing metadata
- accession: 0001746473-25-000097
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000097/0001746473-25-000097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647325000097/plrx-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-25-000097
- JSON: https://secwatch.observer/filing/0001746473-25-000097.json
- Plain text: https://secwatch.observer/filing/0001746473-25-000097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.